Mammary Adenocarcinoma after Ten-Year
Medroxyprogesterone Acetate Supplementation in an Ovariectomized Cat
M Ochota*, M Nowak1,
M Dzieciol and W Nizanski
Department of
Reproduction and Clinic of Farm Animals; 1Department of
Pathology, Faculty of Veterinary Medicine, Wroclaw University of
Environmental and Life Sciences, pl. Grunwaldzki 49, 50-366 Wroclaw,
Poland *Corresponding author:
malgorzata.ochota@up.wroc.pl
Abstract
Mammary tumors are common in feline medicine.
They are often malignant with a high risk of metastasis and guarded prognosis.
Intact females are at greater risk of its development than spayed ones. The
underlying cause is unknown, however there are a few predisposing factors. A
strong relationship was established between progestagens and mammary tumors’
occurrence. It was also proven that gonadectomy prior to first estrus
significantly lowers their incidence. Since, intact females are those to receive
exogenous progestagens, it is difficult to confirm the difference between drug
derived and internally synthesized progestagens and the subsequent pathological
changes. In the reported case, queen received medroxy- progesterone acetate for
10 years, despite it was ovariectomized when one year old. The role of
endogenous reproductive hormones in the etiology of the mammary neoplasia and
CEH is excluded, the mastopathic and metropathic changes, can only be attributed
to the effect of exogenous progestagene administration.